Safety Study in Patients With Advanced Prostate Cancer Treated With FIRMAGON
The primary objective of this observational study was to describe the risk of certain medical events in association with Firmagon treatment in males with a diagnosis of prostate cancer. All participants had a diagnosis for prostate cancer and had made the decision to receive androgen deprivation therapy (ADT) prior to enrolment. Approximately 1,000 participants received FIRMAGON drug, and approximately 500 received a GnRH Agonist as a control group. The study follows participants for up to 5 years, with visits every 3 months for the first 2 years and every 6 months for the last 3 years, across 250 sites in Belgium, France, Hungary, Slovakia and the United Kingdom.
Study design
Cohort - clinical, Cohort
Number of participants at first data collection
1,493 (participants)
Age at first data collection
Varied (participants)
Participant year of birth
Varied (participants)
Participant sex
Male
Representative sample at baseline?
No
Sample features
Countries
Year of first data collection
2011
Primary Institutions
Ferring Pharmaceuticals (Industry, United States of America)
Profile paper DOI
Not available
Funders
Ferring Pharmaceuticals (Industry, United States of America)
Ongoing?
No
Data types collected
- Physical or biological assessment (e.g. blood, saliva, gait, grip strength, anthropometry)
- None
- None
- None
Engagement
Keywords
